Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Finding Solutions to Challenging Cases: Next Steps
Description
The presentation discusses two challenging cases of uncommon blistering conditions, with a focus on their clinical features, diagnosis, and treatment. The first case involves a 60-year-old male who developed blistering after starting several medications for pneumonia. The diagnosis of linear IgA disease was confirmed through skin biopsy, revealing sub-epidermal blistering and a linear pattern of IgA. The case highlighted the importance of identifying drug triggers for linear IgA, transitioning from a focus on vancomycin to considering other medications. Subsequently, the patient was treated with dapsone and prednisone but was readmitted with lower leg weakness, which turned out to be due to prednisone-induced myopathy, revealing a concurrent diagnosis of Guillain-Barré syndrome likely triggered by an influenza vaccine.
The second case centers on a 68-year-old female with a history of type 1 diabetes and renal disease, who presented with facial swelling and ulcerations. Initially treated for suspected cellulitis, her condition led to a suspected diagnosis of lupus. However, upon further evaluation and skin biopsy, a diagnosis of a cryptococcal variant of Sweet syndrome was made. This case underscored the potential overlap in symptoms between lupus and Sweet syndrome, especially in patients taking hydralazine, which can occasionally lead to a trifecta of drug-induced lupus, vasculitis, and Sweet syndrome. The discussions concluded with pearls of wisdom for clinical assessment and treatment considerations of these complex cases.
Conclusions
- Linear IgA Bullous Dermatosis is commonly associated with drug exposures, particularly vancomycin, but can also be triggered by other medications, infections, and autoimmune conditions.
- In cases of Linear IgA, clinicians should look for classic annular lesions, as severe cases can mimic more severe conditions like Stevens-Johnson syndrome (SJS).
- Pulmonary complications and delays in treatment may worsen patient outcomes in cases presenting with blistering conditions.
- Dapsone and prednisone were effective treatments for Linear IgA Bullous Dermatosis but attention must be paid to potential side effects.
- Prednisone-induced myopathy can occur in patients with concurrent autoimmune conditions, complicating diagnosis and management.
- The influenza vaccine has been associated with rare cases of both Linear IgA Bullous Dermatosis and Guillain-Barré Syndrome, suggesting a potential immune mechanism.
- Sweet syndrome can present in various forms and can be confused with other autoimmune dermatologic conditions such as lupus, especially in patients on hydralazine.
- Caution is advised when diagnosing blistering conditions, as overlapping symptoms may lead to misdiagnosis, underscoring the need for a thorough patient history.
- Bolognia, et al. Dermatology. 2025.
- James, et al. Andrew's Diseases of the Skin. 2020.
- Ruiz-Rivero et al. Linear IgA Bullous Dermatosis Presenting as Toxic Epidermal Necrolysis. Actas 2017.
- Jollow et al. Dapsone-induced hemolytic anemia. Drug Metab Rev. 1995.
- Askari et al. Steroid myopathy in connective tissue disease. Am J Med. 1976.
- Daneshmend. The neurotoxicity of dapsone. Adverse Drug React Acute Poisoning Rev. 1984.
- Alberta-Wszolek et al. Linear IgA bullous dermatosis following influenza vaccination. Dermatol Online J. 2009.
- Barrow-Wade et al. Linear IgA bullous dermatosis associated with dermatomyositis. Arch Dermatol. 1992.
- Lasky et al. The Guillain-Barre Syndrome and the 1992-1993 and 1993-1994 influenza vaccines. NEJM, 1998.